NGM Ngm Biopharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NGM

Price (delayed)

$0.7469

Market cap

$61.78M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.83

Enterprise value

$6.23M

NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases and cancer. The ...

Highlights
Ngm Biopharmaceuticals's debt has shrunk by 79% YoY and by 50% QoQ
Ngm Biopharmaceuticals's quick ratio has increased by 21% YoY and by 10% QoQ
NGM's equity is down by 41% year-on-year and by 12% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ngmbio.com
Peers: OMGA

Key stats

What are the main financial stats of NGM
Market
Shares outstanding
82.72M
Market cap
$61.78M
Enterprise value
$6.23M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.36
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$151.14M
EBITDA
-$146.77M
Free cash flow
-$141.15M
Per share
EPS
-$1.83
Free cash flow per share
-$1.71
Book value per share
$2.05
Revenue per share
$0
TBVPS
$2.32
Balance sheet
Total assets
$192.15M
Total liabilities
$22.35M
Debt
$1.38M
Equity
$169.81M
Working capital
$154.69M
Liquidity
Debt to equity
0.01
Current ratio
7.92
Quick ratio
7.68
Net debt/EBITDA
0.38
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-61.8%
Return on equity
-71.8%
Return on invested capital
-102%
Return on capital employed
-89%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NGM stock price

How has the Ngm Biopharmaceuticals stock price performed over time
Intraday
2.23%
1 week
5.94%
1 month
-12.33%
1 year
-86.49%
YTD
-85.12%
QTD
-30.2%

Financial performance

How have Ngm Biopharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$182.53M
Net income
-$151.14M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 14% YoY and by 12% from the previous quarter
The net income has grown by 11% from the previous quarter

Growth

What is Ngm Biopharmaceuticals's growth rate over time

Valuation

What is Ngm Biopharmaceuticals stock price valuation
P/E
N/A
P/B
0.36
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 12% QoQ and by 6% YoY
The stock's price to book (P/B) is 89% less than its 5-year quarterly average of 3.4 and 70% less than its last 4 quarters average of 1.2
NGM's equity is down by 41% year-on-year and by 12% since the previous quarter

Efficiency

How efficient is Ngm Biopharmaceuticals business performance
NGM's return on assets is down by 44% year-on-year and by 2.3% since the previous quarter
The return on equity has declined by 43% year-on-year
The company's return on invested capital fell by 39% YoY

Dividends

What is NGM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NGM.

Financial health

How did Ngm Biopharmaceuticals financials performed over time
Ngm Biopharmaceuticals's total liabilities has plunged by 55% YoY and by 21% from the previous quarter
The company's total assets fell by 43% YoY and by 13% QoQ
Ngm Biopharmaceuticals's debt is 99% lower than its equity
Ngm Biopharmaceuticals's debt has shrunk by 79% YoY and by 50% QoQ
NGM's debt to equity has dropped by 50% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.